全球重組疫苗市場規模、佔有率、成長分析，依最終用戶（兒童和成人）、配銷通路（醫院和疫苗接種中心）- 2024-2031 年行業預測

Global Recombinant Vaccines Market Size, Share, Growth Analysis, By End user(Pediatric and Adult), By Distribution channel(Hospitals and Vaccination centers) - Industry Forecast 2024-2031

出版日期: 2024年03月17日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球重組疫苗市場規模為90.2億美元，預計將從2023年的100.5億美元成長到2031年的238.3億美元，預測期間（2024-2031年）複合年成長率為11.40%。

過去，早期的疫苗嚴重依賴將個體暴露於減弱或去活化的病原體的方法。然而，隨著基因工程、基因組學和重組 DNA 技術的出現，疫苗開發的格局發生了深刻的轉變。這些創新方法催生了現已上市的新疫苗。與傳統方法不同，這些疫苗是在受控實驗室環境中製作的，利用基因篩檢技術來減輕與傳染病相關的風險。這不僅提高了疫苗的功效，也高度重視疫苗接種過程中的安全性。基因工程和疫苗開發的融合標誌著一項重大進步，使免疫接種方法更加精確和有針對性。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 拉丁美洲其他地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- MEA 的其餘部分

競爭格局

前 5 名企業比較
2021 年關鍵參與者的市場定位
主要市場參與者所採取的策略
最佳制勝策略
近期市集活動
主要公司市佔率（%），2021年

主要公司簡介

AstraZeneca Plc.
Dynavax Technologies Corporation
Emergent BioSolutions Inc.
GlaxoSmithKline Plc.
Johnson & Johnson, Merck & Co. Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Serum Institute of India Pvt. Ltd.

簡介目錄

Product Code: SQMIG35A2767

Global Recombinant Vaccines Market size was valued at USD 9.02 Billion in 2022 and is poised to grow from USD 10.05 Billion in 2023 to USD 23.83 Billion by 2031, at a CAGR of 11.40% during the forecast period (2024-2031).

In the past, early vaccines heavily relied on methods that involved exposing individuals to weakened or deactivated pathogens. However, with the emergence of genetic engineering, genomics, and recombinant DNA technologies, the landscape of vaccine development has undergone a profound transformation. These innovative approaches have led to the creation of new vaccines now available in the market. Unlike traditional methods, these vaccines are crafted in controlled laboratory environments, leveraging genetic screening techniques to mitigate the risks associated with infectious diseases. This not only enhances vaccine efficacy but also places a paramount emphasis on safety during the vaccination process. The fusion of genetic engineering and vaccine development marks a significant advancement, enabling a more precise and targeted approach to immunization.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Recombinant Vaccines Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Recombinant Vaccines Market Segmental Analysis

On the basis of indication, the market is classified into human papillomavirus, meningococcal and others. On the basis of end user, the market is bifurcated into pediatric and adult. On the basis of distribution channel, the market is classified into hospitals and vaccination centers. Region wise, the market is studied across North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa.

Drivers of the Global Recombinant Vaccines Market

A key factor driving market growth is the widespread use of recombinant properties, which significantly improve the effectiveness and safety of vaccines administered to patients. The inherent advantages of this technology enable rapid and large-scale vaccine production, reducing the risk of supply shortages. Additionally, these vaccines lack infectious viral particles, making them safe for individuals with compromised immune systems. The significant benefits of recombinant vaccines have prompted manufacturers to prioritize the development of innovative products targeting viral diseases. This effort involves harnessing advanced DNA technology, genomics, and other cutting-edge biotechnological techniques, collectively contributing to the development of more effective and safer vaccines.

Restraints in the Global Recombinant Vaccines Market

Despite the increased incidence of chronic and infectious diseases, the widespread uptake of vaccines is hindered by several factors, notably the exorbitant cost per dose. Despite the diligent efforts of international organizations in distributing millions of doses worldwide, the prohibitive expense of vaccination remains a significant obstacle for numerous populations. Despite concerted endeavors to ensure global coverage, certain regions still struggle with vaccine accessibility due to the enduring issue of high costs.

Market Trends of the Global Recombinant Vaccines Market

The rising prevalence of infectious diseases globally has sparked a critical need for efficient vaccines. This necessity is heightened by the heightened vulnerability of elderly and pediatric populations to severe illnesses, emphasizing the urgent requirement for swift vaccination initiatives on a global scale. Organizations like UNICEF and PAHO have been pivotal in distributing millions of vaccine doses to nations confronting urgent requirements, bolstering efforts to halt the spread of various diseases. Their effective procurement strategies have significantly curbed disease transmission and fortified communities against these health hazards.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Recombinant Vaccines Market by End user

Market Overview
Pediatric and Adult

Global Recombinant Vaccines Market by Distribution channel

Market Overview
Hospitals and Vaccination centers

Global Recombinant Vaccines Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

AstraZeneca Plc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dynavax Technologies Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline Plc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson, Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novavax, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Serum Institute of India Pvt. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments